News
The proposed transaction values VERAXA Biotech AG at USD 1.64 billion with expected gross cash proceeds up to USD 253 million held in trust by Voyager Acquisition Corp.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback